Example ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 5 | Progressive supranuclear palsy | 1 |
5. Progressive supranuclear palsy
Clinical trials : 89 / Drugs : 107 - (DrugBank : 40) / Drug target genes : 65 - Drug target pathways : 108
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2000041207 | 2021-01-01 | 2020-12-22 | A registered cohort study on progressive supranuclear palsy (PSP) | A registered cohort study on progressive supranuclear palsy (PSP) | progressive supranuclear palsy | Gold Standard:Diagnostic criteria of MDS for progressive supra-nuclear palsy (2017) and the Chinese clinical diagnostic criteria for progressive supra-nuclear palsy (2016).;Index test:The progression of PSP rating scales. Tau protein-related pathological examination (for example, Tau protein content in blood, Tau protein-related detection in cerebrospinal fluid in patients with cognitive impairment, etc.), and brain Tau PET imaging.; | Huashan Hospital, Fudan University | NULL | Recruiting | 40 | 85 | Both | Target condition:100;Difficult condition:0 | China |